Sheila Febriana, Asvin Nurulita, Uleng Bahrun


Troponin I is a cardiac biomarker recomended by The Third Global Myocardial Infarction Task Force World Health Organisation
(WHO). Troponin plays a central role as a relevant biomarker that require reliable samples, methods, device and efficiency of time.
Selecting the device, methods and sample used in the assay may affect the results and turn arround time. The aim of this study is to
know troponin I result using Point of care Testing device with a flourescence immunoassay methods using whole blood and laboratorybased
analysis device with Enzyme-Linked Fluorescent Assay (ELFA) methods using serum by evaluation. Cross sectional study was held
on 50 subjects in Wahidin Sudirohusodo hospital during the period between July-August 2015, those who suspected suffering acute
coronary syndome (ACS) and underwent troponin I test ordered by the physician and also had whole blood sample. The subjects are
around 51.96±12.80 year old and most of them are men (62%). The mean consentration of troponin I with laboratoric-based analysis is
0.50±1.69 μg/L and with POCT is 0.51±1.77. The Pearson correlation test shows the correlation (r) is 0.99 with the p value is <0.001.
Bland and Altman methods show the mean difference between two assays is 0.014μg/L (95% confidence interval, -0.015; 0.043) with
the limit of agreement -0.19 to 0.22. Based on this study, it can be concluded that troponin I assay using POCT device can be used to
support ACS diagnosis precisely and rapidly. It is suggested to perform futher study with concern on the patient’s clinical condition as
well as the diagnosis, so it can evaluate the device performance to measure troponin I levels consistently with the clinical condition.


Troponin I, acute coronary synndrome, point of care testing, whole blood

Full Text:




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.